Embark Early Education Ltd

The biopharma sector has seen 955 deals worth $114.5 billion through early August 2022, with deal values up but numbers down compared to previous years. Immunotherapies and RNA technologies drive major deals, including a $6.2 billion agreement between Poseida Therapeutics and Roche. Despite a volatile economy, the industry focuses on transformative therapies, with significant investments in curative treatments and a shift towards venture capital financing. FDA approvals are down, but the sector anticipates future breakthroughs in patient care.

The drug discovery technologies market is projected to grow from $66.08 billion in 2023 to $108.31 billion by 2028, driven by advancements in genomic research, AI, and precision medicine. Key trends include AI integration, 3D cell culture, and blockchain for data security. Market drivers include the rising prevalence of chronic diseases and the development of advanced technologies by companies like Google.

Life sciences sector resilient despite challenges; significant investments in ADCs, CGTs, AI, and CDMOs. ADCs and CGTs driving growth, with China leading in clinical trials and innovation. AI transforming drug discovery and clinical trials. APAC region dominating clinical trials, especially in oncology. China's biopharma sector booming, attracting global investments. CDMOs adopting digital revolution and AI for agile manufacturing. BIOSECURE Act impacting Chinese biotech companies, benefiting Indian CDMOs.

Enterprise Therapeutics' ETD001, an inhaled ENaC blocker, shows promise in Phase 2 trials for cystic fibrosis treatment, potentially improving lung function and mucus hydration.

Evotec, a dual-model biotech company facing financial struggles, has attracted acquisition interest from Triton Partners and Halozyme Therapeutics. Despite Evotec's preference for independence, the company's unique position as both a service provider and asset developer raises concerns about its future role in the biotech industry if acquired.

Novartis acquires Kate Therapeutics for $1.1B, Barclays predicts challenging 2025 for European pharma, Trump picks surgeon Martin Makary to lead FDA, Novartis partners with Ratio Therapeutics for up to $745M, Kyowa Kirin pays Kura Oncology $330M upfront for leukemia drug rights, global measles cases rise 20% to 10.3 million, Brookfield considers €7B bid for Grifols, Bavarian Nordic's 2025 order book reaches €320M, FDA supports REGENXBIO's Duchenne muscular dystrophy gene therapy, Merck's subcutaneous Keytruda matches infused version, Syndax Pharmaceuticals secures FDA approval for Revuforj, Aclaris Therapeutics licenses 2 antibodies from Biosion for over $40M upfront, Sandoz to cut 10% of workforce in France, Incyte halts testing and discontinues drugs, Sage Therapeutics discontinues dalzanemdor, Johnson & Johnson and Merck announce job cuts in China, Samsung Biologics signs $668M contracts, FDA grants accelerated approval to Jazz Pharmaceuticals' Ziihera, Lexicon Pharmaceuticals cuts 60% of workforce, Halozyme withdraws €2B bid for Evotec, mpox epidemic overwhelms hospitals in Kinshasa.

Halozyme withdrew offer to buy Evotec after refusal to engage; Neurogene's Rett syndrome gene therapy patient died from side effects; Argenx advances efgartigimod testing in myositis; Kyowa Kirin pays $330M upfront for Kura Oncology's leukemia drug; FDA's Douglas Throckmorton plans to retire.

Kuwait in vivo CRO market generated USD 5.8 million in 2023, expected to reach USD 9.8 million by 2030 with a CAGR of 7.7%. Small molecule was the largest segment in 2023, while Large Molecule is the fastest growing. Kuwait accounted for 0.1% of the global market in 2023, with the U.S. leading globally and South Africa leading in the Middle East & Africa by 2030.

The South Korea in vivo CRO market generated USD 36.1 million in 2023, projected to reach USD 65.9 million by 2030, growing at a CAGR of 9%. Small molecule was the largest segment in 2023, while Large Molecule is expected to grow fastest. South Korea accounted for 0.8% of the global market in 2023, with the U.S. leading globally and Japan leading in Asia Pacific by 2030. India is the fastest-growing regional market in Asia Pacific, projected to reach USD 122.7 million by 2030.

France in vivo CRO market generated USD 230.2 million in 2023, expected to reach USD 399.6 million by 2030 with an 8.2% CAGR. Small molecule led in 2023, while Large Molecule is fastest growing. Factors driving growth include increasing preclinical studies, outsourcing, skilled professionals, and R&D investments.